AstraZeneca, Alexion close massive $39B merger; bluebird bio earns EU nod for Lenti-D as big split approaches
With the final hurdle recently cleared, AstraZeneca and Alexion can finally celebrate their $39 billion merger.
The drugmakers closed their major M&A pact Wednesday, with Alexion formally taking its place as the British drug giant’s rare disease unit. The UK’s Competition & Markets Authority last week gave its stamp of approval to the deal, marking the last significant regulator to sign off.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
